HYDERABAD: In a move aimed at strengthening drug safety and regulatory standards, the US Food and Drug Administration (USFDA) and the Drugs Control Administration (DCA), Telangana, held a joint meeting in Hyderabad to exchange best practices in pharmaceutical regulation and public health monitoring.
The interaction took place at the DCA headquarters in Vengal Rao Nagar, where officials from both sides discussed ways to improve inspection systems, manufacturing standards, and regulatory compliance in the pharmaceutical sector. The meeting is part of ongoing cooperation between the two agencies to enhance the quality and safety of medicines.
According to officials, the main focus of the discussion was on Good Manufacturing Practices (GMP), which are globally accepted standards used to ensure that medicines are produced safely and consistently. USFDA experts shared insights into advanced inspection techniques and global regulatory frameworks, while Telangana officials presented their recent initiatives in drug control and inspection methods.
The DCA team also highlighted its work related to Revised Schedule M norms, along with inspections of sterile manufacturing facilities and emerging trends in pharmaceutical production. These updates were shared as part of efforts to align state-level practices with international standards.
Officials said the exchange helped strengthen the understanding of USFDA regulatory expectations among DCA inspectors, especially in areas related to quality control, compliance checks, and manufacturing oversight. The discussions are expected to improve coordination between the two bodies in the future.
The meeting is also seen as part of a broader effort to ensure safer and higher-quality pharmaceutical production, particularly in a region that hosts a large number of drug manufacturing units catering to both domestic and global markets.
Experts noted that such regulatory collaborations are important because they help local authorities adopt global best practices, improve inspection systems, and reduce risks related to substandard or unsafe medicines entering the market. Officials added that continued engagement between the USFDA and DCA will help strengthen public health systems, drug safety mechanisms, and regulatory transparency in the long run.
The forum marks another step in ongoing cooperation between the two agencies, which have previously worked together on initiatives aimed at improving pharmaceutical standards and regulatory enforcement.
With this exchange, both regulators aim to build a more robust and globally aligned drug safety framework, ensuring better compliance and stronger safeguards for public health.
